Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business Officer
Terumo Blood and Cell Technologies (Terumo BCT) has appointed Patrick Daly as its new Chief Business Officer. With over 30 years of healthcare industry experience, Daly joins from IQVIA where he built the MedTech Global Data franchise.
Prior to IQVIA, Daly served as President and CEO of Cohera Medical and currently maintains a position as independent Board Director for BioStem Technologies. His extensive career includes senior leadership roles at Johnson & Johnson in strategic marketing, sales, and business development. Daly holds a Bachelor of Science in Foreign Area Studies from West Point.
According to CEO Antoinette Gawin, Daly's expertise in capital acquisition, strategic partnerships, and data monetization positions him to integrate offerings and drive innovation. The appointment aligns with Terumo BCT's ambitions for double-digit growth and its mission to address global healthcare challenges through enhanced disease research, therapeutic development, and blood safety initiatives.
Terumo Blood and Cell Technologies (Terumo BCT) ha nominato Patrick Daly come nuovo Chief Business Officer. Con oltre 30 anni di esperienza nel settore sanitario, Daly arriva da IQVIA, dove ha sviluppato la divisione MedTech Global Data.
Prima di IQVIA, Daly è stato Presidente e CEO di Cohera Medical e attualmente ricopre il ruolo di membro indipendente del consiglio di amministrazione di BioStem Technologies. La sua lunga carriera include posizioni di leadership senior in Johnson & Johnson, con responsabilità in marketing strategico, vendite e sviluppo commerciale. Daly è laureato in Foreign Area Studies presso West Point.
Secondo la CEO Antoinette Gawin, l’esperienza di Daly in acquisizione di capitali, partnership strategiche e monetizzazione dei dati lo rende ideale per integrare le offerte e promuovere l’innovazione. Questa nomina è in linea con le ambizioni di Terumo BCT di una crescita a doppia cifra e con la sua missione di affrontare le sfide sanitarie globali attraverso la ricerca sulle malattie, lo sviluppo terapeutico e le iniziative per la sicurezza del sangue.
Terumo Blood and Cell Technologies (Terumo BCT) ha nombrado a Patrick Daly como su nuevo Chief Business Officer. Con más de 30 años de experiencia en la industria sanitaria, Daly llega desde IQVIA, donde desarrolló la franquicia MedTech Global Data.
Antes de IQVIA, Daly fue presidente y CEO de Cohera Medical y actualmente es director independiente en el consejo de BioStem Technologies. Su amplia trayectoria incluye cargos ejecutivos en Johnson & Johnson en marketing estratégico, ventas y desarrollo comercial. Daly tiene una licenciatura en Foreign Area Studies de West Point.
Según la CEO Antoinette Gawin, la experiencia de Daly en adquisición de capital, alianzas estratégicas y monetización de datos lo posiciona para integrar ofertas y fomentar la innovación. Este nombramiento se alinea con las metas de crecimiento de dos dígitos de Terumo BCT y su misión de abordar los desafíos globales de salud mediante la investigación de enfermedades, el desarrollo terapéutico y las iniciativas de seguridad sanguínea.
Terumo Blood and Cell Technologies (Terumo BCT)는 Patrick Daly를 새로운 Chief Business Officer로 임명했습니다. 30년 이상의 의료 산업 경력을 가진 Daly는 IQVIA에서 MedTech Global Data 사업을 구축한 경력이 있습니다.
IQVIA 이전에는 Cohera Medical의 사장 겸 CEO로 재직했으며 현재 BioStem Technologies의 독립 이사로 활동 중입니다. 그의 폭넓은 경력에는 Johnson & Johnson에서 전략 마케팅, 영업 및 사업 개발 분야의 고위 리더십 역할이 포함되어 있습니다. Daly는 West Point에서 Foreign Area Studies 학사 학위를 받았습니다.
CEO Antoinette Gawin에 따르면, Daly의 자본 조달, 전략적 파트너십 및 데이터 수익화 전문성은 제품 통합과 혁신 추진에 적합하다고 합니다. 이번 임명은 Terumo BCT의 두 자릿수 성장 목표와 질병 연구, 치료 개발, 혈액 안전성 향상을 통한 전 세계 보건 문제 해결이라는 미션에 부합합니다.
Terumo Blood and Cell Technologies (Terumo BCT) a nommé Patrick Daly en tant que nouveau Chief Business Officer. Fort de plus de 30 ans d’expérience dans le secteur de la santé, Daly rejoint l’entreprise après avoir développé la franchise MedTech Global Data chez IQVIA.
Avant IQVIA, Daly a été président et CEO de Cohera Medical et occupe actuellement un poste d’administrateur indépendant au sein du conseil d’administration de BioStem Technologies. Sa carrière riche comprend des postes de direction chez Johnson & Johnson dans le marketing stratégique, les ventes et le développement commercial. Daly est titulaire d’un Bachelor of Science en Foreign Area Studies de West Point.
Selon la CEO Antoinette Gawin, l’expertise de Daly en acquisition de capitaux, partenariats stratégiques et monétisation des données lui permet d’intégrer les offres et de stimuler l’innovation. Cette nomination s’inscrit dans les ambitions de Terumo BCT pour une croissance à deux chiffres et sa mission de relever les défis mondiaux de santé grâce à la recherche sur les maladies, le développement thérapeutique et les initiatives de sécurité sanguine.
Terumo Blood and Cell Technologies (Terumo BCT) hat Patrick Daly zum neuen Chief Business Officer ernannt. Daly bringt über 30 Jahre Erfahrung in der Gesundheitsbranche mit und kommt von IQVIA, wo er die MedTech Global Data-Sparte aufgebaut hat.
Vor IQVIA war Daly Präsident und CEO von Cohera Medical und ist derzeit unabhängiges Vorstandsmitglied bei BioStem Technologies. Seine umfangreiche Karriere umfasst Führungspositionen bei Johnson & Johnson in den Bereichen strategisches Marketing, Vertrieb und Geschäftsentwicklung. Daly hat einen Bachelor of Science in Foreign Area Studies von West Point.
CEO Antoinette Gawin zufolge qualifizieren Daly’s Expertise in Kapitalbeschaffung, strategischen Partnerschaften und Datenmonetarisierung ihn dazu, Angebote zu integrieren und Innovationen voranzutreiben. Die Ernennung steht im Einklang mit Terumo BCTs Ziel eines zweistelligen Wachstums und der Mission, globale Gesundheitsherausforderungen durch verbesserte Krankheitsforschung, therapeutische Entwicklung und Blutsicherheitsinitiativen zu bewältigen.
- None.
- None.
Daly, a 30-year veteran of the healthcare industry, is the latest leadership addition to help Terumo BCT unite business areas and fuel enterprise growth
Daly has spent his career building commercial capabilities to deliver organic and inorganic growth. Before joining IQVIA, he was President and CEO of Cohera Medical, and he remains an independent Board Director for BioStem Technologies. He has held successive senior leadership roles in strategic marketing, sales and business development across various regions and businesses of Johnson & Johnson. He earned his Bachelor of Science in Foreign Area Studies from the
"Patrick's experience acquiring capital and building strategic partnerships complements his experience monetizing data and solutions. This uniquely positions him to integrate our offerings and drive innovation across our business models and go-to-market strategies," said Antoinette Gawin, President and Chief Executive Officer of Terumo BCT. "His diverse experience will help accelerate our ambitions for double-digit growth."
"It is a great moment to join Terumo BCT as it continues executing its long-term vision for growth and to meet patients' unmet needs globally," said Daly. "I am focused on ensuring our full portfolio, connected with data, software and services, will play a growing role in helping our customers solve healthcare's toughest challenges, while advancing disease research, therapeutic development and improved access to safe blood worldwide."
About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees worldwide believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.
Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 150 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.
We have global headquarters in
View original content to download multimedia:https://www.prnewswire.com/news-releases/terumo-blood-and-cell-technologies-names-patrick-daly-as-chief-business-officer-302430575.html
SOURCE Terumo Blood and Cell Technologies
FAQ
What is Patrick Daly's new role at Terumo BCT (TRUMY)?
What is Patrick Daly's professional background before joining TRUMY?
What are Terumo BCT's (TRUMY) growth targets under the new leadership?
How will Patrick Daly contribute to Terumo BCT's (TRUMY) business strategy?
What educational background does the new TRUMY Chief Business Officer have?
